Navigation Links
SeraCare Introduces New Hepatitis C ACCUVERT Seroconversion Panels and Anti-Herpes ACCUSET Performance Panel
Date:5/15/2013

Milford, Massachusetts (PRWEB) May 15, 2013

SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, announced it has launched three new ACCUVERT™ seroconversion panels and one new ACCUSET™ performance panel. These product additions expand the company’s offerings that assist in vitro diagnostics manufacturers in challenging new and existing assays.

“As new therapeutics in the drug discovery pipeline are increasingly tailored by genotype, SeraCare is responding with ACCUVERT seroconversion panels that provide the diverse, genotype-specific material our customers require as part of their rigorous regulatory submission process,” said Kim Anderson, Product Manager, IVD Research Business Unit at SeraCare. “We’re equally committed to building out our industry-leading line of ACCUSET performance panels targeted at the infectious disease areas of greatest interest to researchers today.”

SeraCare’s three new Hepatitis C ACCUVERT seroconversion panels provide manufacturers with material from a variety of donor genotypes and recent collection periods. Each panel demonstrates how a single donor responds in the presence of the disease during the collection period, with a graphical depiction of seroconversion. Product data sheets also offer comparative data that is valuable in reviewing test results from a number of industry leading assays. The new Hepatitis C ACCUVERT seroconversion panels include:    

  •     HCV Seroconversion Panel PHV924, providing undiluted plasma samples from a single male donor of genotype 2b, drawn over an 88-day period in 2008
  •     HCV Seroconversion Panel PHV925, providing undiluted plasma samples from a single male donor of genotype 1a, drawn over a 27-day period in 2008
  •     HCV Seroconversion Panel PHV926, providing undiluted plasma samples from a single male donor of genotype 3a, drawn over a 14-day period in 2009

SeraCare also released a new Anti-Herpes Mixed Titer Performance Panel of naturally occurring, well-characterized plasma and serum specimens for use in developing, evaluating and troubleshooting anti-HSV 1/2, anti-HSV 1 and anti-HSV 2 assays. The 21-member panel represents a broad range of reactivity to anti-HSV 1/2 IgG and IgM markers, from negative to strongly positive. Comprehensive test results for multiple industry assays are provided for comparative purposes.    

The SeraCare line of ACCUVERT seroconversion panels – designed to help diagnostics manufacturers and clinical labs evaluate, monitor and troubleshoot test and staff performance – includes a variety of options for HIV, Hepatitis A, Hepatitis B, Hepatitis C and West Nile Virus. SeraCare ACCUSET performance panels encompass a broad range of highly characterized, disease state patient samples designed for use with most instrument platforms and test methods.

SeraCare’s new Hepatitis C ACCUVERT seroconversion panels and Anti-Herpes ACCUSET performance panel are available immediately worldwide. For more information, contact SeraCare Customer Service at 1-800-676-1881 or visit http://www.seracare.com.

About SeraCare Life Sciences, Inc.

SeraCare, a portfolio company of Linden Capital Partners, partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics. For more information, visit http://www.seracare.com.

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at http://www.lindenllc.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10734750.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
2. SeraCare Shareholders Approve Acquisition by Linden Capital Partners
3. SeraCare Life Sciences Sharpens Focus on Diagnostics Industry
4. SeraCare Life Sciences Divests Biorepository Business
5. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
6. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
7. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
8. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
9. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
10. Profit Lifter for Pro Mold Removers: Molderizer Introduces Remediation Product Like No Other
11. JPSA Introduces Picosecond Laser Micromachining System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
Breaking Biology News(10 mins):